Tarix secures orphan-drug status for peptide drug candidate

09/27/2011 | Mass High Tech (Boston)

Tarix Pharmaceuticals received orphan-drug designation from the FDA to use experimental peptide drug TXA127 in patients with pulmonary arterial hypertension. In June 2010, the company obtained the same status for the drug as treatment for myelodysplastic syndromes and engraftment of people undergoing a stem cell transplant.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL